Published in Onco Targets Ther on May 02, 2014
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med (1991) 19.46
p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer (2009) 9.21
External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol (2008) 2.85
Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol (2011) 2.10
p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell (2006) 1.90
p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol (2007) 1.81
Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. J Urol (2009) 1.73
A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion. Breast Cancer Res (2012) 1.70
External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology. J Urol (2011) 1.69
Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res (2004) 1.51
Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol (2004) 1.42
Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev (2009) 1.23
Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer (2002) 1.23
Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res (1999) 1.21
High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer (2006) 1.20
Genetic and epigenetic alterations during renal carcinogenesis. Int J Clin Exp Pathol (2010) 1.11
Expression of survivin in renal cell carcinomas: association with pathologic features and clinical outcome. Urology (2007) 1.09
Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma. Eur Urol (2009) 1.07
Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin Cancer Res (2009) 1.06
Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br J Cancer (2009) 1.03
Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma. Urology (2007) 1.02
TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor. Urology (2012) 1.00
Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival. Br J Cancer (1999) 0.97
Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression. Am J Surg Pathol (2007) 0.95
A new staging system for locally advanced (pT3-4) renal cell carcinoma: a multicenter European study including 2,000 patients. J Urol (2007) 0.92
Expression of the cell cycle proteins p21, p27, and pRb in clear cell renal cell carcinoma and their prognostic significance. Urology (2001) 0.92
Predicting outcomes in renal cell carcinoma. Curr Opin Urol (2005) 0.91
Evaluation of CD31 (PECAM-1) expression using tissue microarray in patients with renal cell carcinoma. Tumour Biol (2007) 0.88
Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer (2005) 0.88
Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma. Cancer Biomark (2010) 0.86
Immunohistochemical analysis of prognostic protein markers for primary localized clear cell renal cell carcinoma. Cancer Invest (2013) 0.85
Avoiding Pitfalls in the Statistical Analysis of Heterogeneous Tumors. Biomed Inform Insights (2009) 0.81
pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival. Cancer (2002) 0.80
Prognostic significance of ploidy, MIB-1 proliferation marker, and p53 in renal cell carcinoma. J Am Coll Surg (2005) 0.80
Splenunculus Masquerading as Prostate-specific Membrane Antigen-positive Lymph Node Metastasis in a Patient With Prostate-specific Antigen Relapse After Radical Prostatectomy. Urology (2016) 0.79
Correlation Between Minimum Apparent Diffusion Coefficient (ADCmin) and Tumor Cellularity: A Meta-analysis. Anticancer Res (2017) 0.78
Correlation between apparent diffusion coefficient (ADC) and cellularity is different in several tumors: a meta-analysis. Oncotarget (2017) 0.78
CT-defined low-skeletal muscle mass as a prognostic marker for survival in prostate cancer: A systematic review and meta-analysis. Urol Oncol (2021) 0.75
Correlation between apparent diffusion coefficient (ADC) and cellularity is different in several tumors: a meta-analysis. Oncotarget (2017) 0.75
Prospective comparison of transperineal MRI/ultrasound-fusion biopsy and transrectal systematic biopsy in biopsy-naïve patients. BJU Int (2017) 0.75